LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

Strona główna・Stock List・Biogen Inc

Biogen Inc

Closed

Sector Healthcare

200.08 -0.66

Buy Sell

Overview

Share price change

24h

Current

Min

199.46

Max

200.85

Key metrics
By Trading Economics
Income	190M 584M
Sales	180M 2.5B
P/E Sector Avg	28.98 103.001
EPS	5.28
Profit margin	23.628
Employees	7,570
EBITDA	237M 919M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+37 upside

Market Stats
By TradingEconomics
Market Cap	122M 30B
Previous open	200.74
Previous close	200.08

News Sentiment

By Acuity

34%

66%

64 / 365 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

198.19 / 204.86 Support & Resistance

Biogen Inc Chart

Related News

6 wrz 2024, 11:00 UTC

Peer Comparison

Price change

Biogen Inc Forecast

Price Target

By TipRanks

37% upside

12 Months Forecast

Average 275.11 USD 37%

High 342 USD

Low 190 USD

Based on 19 Wall Street analysts offering 12 month price targets forBiogen Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

19 ratings

Buy

Hold

Sell

Based on 19 analysts giving stock ratings to Biogen Inc - Dist in the past 3 months.

Technical Score

By Trading Central

198.19 / 204.86Support & Resistance

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

All events are bearish.

Sentiment

By Acuity

64 / 365 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Biogen Inc

Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company's marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA). It also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions; GAZYVA indicated for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of primary progressive MS (PPMS) and relapsing MS (RMS), and other anti-CD20 therapies. The Company's pipeline includes BIIB074; BAN2401; BIIB061; BIIB067, BIIB124, BIIB074, BIIB118 and TMS-007.